Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Novartis

Sales up 2% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis
1Q Revenues: $11.1 billion (+2%)
1Q Earnings: $1.8 billion (-13%)
Comments: Growth was driven by Cosentyx ($791 million, +36%), Entresto ($357 million, +79%), Lutathera (sales of $106 million), Promacta ($307 million, +19%) and Kisqali (sales of $91 million), partly offset by the negative impacts of pricing and generic competition. Tasigna sales were down 7% to $434 million. Sandostatin sales were down 2% to $392 million. Gleevec sales were down 22% to $307 million. Exjade sales were down 9% to 238 million. Votrient sales were down 13% to $187 million. Gilenya sales were $766 million, down 7%, as volume growth in EU was offset by a decline in U.S. due to competitive pressures. Lucentis sales were $533 million, up 2%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters